Kymos Group

🌙🔵 Yesterday, Kymos Group had the pleasure of attending this year’s edition of #NitCataloniaHealth, the event that welcomes owners, executives, investors, and other stakeholders in Catalonia’s #biomedicine, #health, and #lifesciences sectors. As always, we’d like to take a moment to congratulate the #CATALONIAHEALTH award winners of this edition for their achievements and milestones in 2024. A big congratulations to OXOLIFE and Hospital Sant Joan de Déu Barcelona. 👏 A heartfelt thank you to the Catalonia.Health (CataloniaBio & HealthTech) team for organizing such a fantastic event, and to all our colleagues and friends. We look forward to seeing you again at the 2026 gala! #WeAreCataloniaHealth

🆕📑 Dr. Ron Wacker, General Manager of our German Site, has prepared an article showcasing the strategic importance of outsourcing analytical testing to Contract Research Organizations (CROs). Outsourcing helps pharmaceutical and biotech companies streamline development, ensure quality, and stay compliant—making CRO partnerships a key strategic advantage. 🔽 Read more about it in the full article below:

📢 JOB OFFER We are #hiring a Scientist for our Bioanalysis Department The candidate will be assigned the following responsibilities: - Design, develop, and supervise LC-MS/MS bioanalytical methods for compound determination in biological matrices. - Develop and validate new analytical methods using HPLC-UV. - Manage projects directly with clients, ensuring timely and quality delivery. Requirements: - Degree in Analytical Chemistry with a specialization in Mass Spectrometry. - Proficiency in compound quantification by LC-MS/MS. - Experience with HPLC-UV analysis and method development. - Familiarity with GLP regulations will be valued - At least 1 year of experience as a Scientist in a pharmaceutical environment. - Fluent in professional English. Join our team today! Apply using the link below 👇 🔗 https://lnkd.in/dYgv2859

▶️ 𝐓𝐫𝐚𝐧𝐬𝐠𝐞𝐧𝐞/𝐆𝐞𝐧𝐨𝐦𝐞 𝐂𝐡𝐚𝐫𝐚𝐜𝐭𝐞𝐫𝐢𝐳𝐚𝐭𝐢𝐨𝐧 - Verifying genetic identity and purity Earlier this week, we introduced our experience on capsid protein analysis of #ViralVectors. Following our #AdvancedTherapies series, today we’ll be focusing on transgene/genome characterization. 💡 The transgene or genome of a viral vector is its core functional component, containing all the information and therapeutic instructions that will be transferred to the target cells. Establishing its purity and identity is essential for #GeneTherapy success. At Kymos Group, we offer state-of-the-art transgene and genome characterization, including: ✔ Size identity & purity analysis by Gel Capillary Electrophoresis with Laser Induced Fluorescence (GCE-LIF) ✔ Transgene sequencing & DNA impurity testing by Next-Generation Sequencing (NGS) ✔ Transgene quantitation by qPCR ✔ Total DNA quantitation by fluorescence methods We are fully committed to delivering a high quality service with tight timelines and sustainable prices for #ATMP analysis. To learn more or get in touch with us, visit our dedicated webpage: https://lnkd.in/dmMmQdwd

▶️ 𝐂𝐚𝐩𝐬𝐢𝐝 𝐏𝐫𝐨𝐭𝐞𝐢𝐧𝐬 𝐂𝐡𝐚𝐫𝐚𝐜𝐭𝐞𝐫𝐢𝐳𝐚𝐭𝐢𝐨𝐧 – Ensuring Structural Integrity Last week, we introduced our new series on #AdvancedTherapies, which focuses on the key aspects of #ViralVector characterization and our expertise in the field. Today, we'll continue with capsid protein analysis. 🔎 Capsids of viral vectors are constituted of proteins - encapsulating and protecting the genetic material inside and enabling efficient delivery to the target cells. Their integrity and identity must be assessed by commonly used protein characterization techniques. Kymos Group provides cutting-edge capsid protein characterization, including: ✔ Molecular weight determination of protein constituents by LC-HRMS ✔ Correct ratio of protein constituents and purity by GCE and SDS-PAGE ✔ Amino acid sequencing by LC-MS/MS With these state-of-the-art techniques, we guarantee your viral vectors have the highest quality, and meet regulatory standards. To learn more or get in touch with us, visit our dedicated webpage: https://lnkd.in/dmMmQdwd #AdvancedTherapies #ATMP #GeneTherapy #ViralVectors #CapsidProteins

▶ This week, we had the pleasure of hosting a delegation from our valued client and partner, Agios Pharmaceuticals, at our sites in Italy and Spain. During their visit, we welcomed them into our laboratories and provided an in-depth tour of our state-of-the-art facilities and equipment in Ancona and Barcelona. This visit was another step in strengthening our partnership, and we look forward to many more years of collaboration!

🔬 Viral vectors are at the core of #GeneTherapy, providing an ideal method for delivering genes to target cells. Their natural design makes them very effective at entering a cell and delivering its genetic material. As with other #ATMPs, ensuring their quality, integrity, and safety is critical for regulatory approval and clinical success. At Kymos Group, we have a specialized and dedicated team focused on Viral Vector Characterization with expertise in Adeno-associated virus, Adenovirus, and Lentivirus testing, and we've recently launched our new service page (🔗 https://bit.ly/4aS0NMn). ▶️ From today, we'll start a post series in which we’ll break down the key aspects of Viral Vector Characterization and our experience with it, covering the following: ✔ 𝐂𝐚𝐩𝐬𝐢𝐝 𝐏𝐫𝐨𝐭𝐞𝐢𝐧𝐬 𝐂𝐡𝐚𝐫𝐚𝐜𝐭𝐞𝐫𝐢𝐳𝐚𝐭𝐢𝐨𝐧 – Ensuring integrity and identity ✔ 𝐓𝐫𝐚𝐧𝐬𝐠𝐞𝐧𝐞/𝐆𝐞𝐧𝐨𝐦𝐞 𝐂𝐡𝐚𝐫𝐚𝐜𝐭𝐞𝐫𝐢𝐳𝐚𝐭𝐢𝐨𝐧 – Verifying genetic identity and purity. ✔ 𝐄𝐧𝐭𝐢𝐫𝐞 𝐕𝐢𝐫𝐚𝐥 𝐕𝐞𝐜𝐭𝐨𝐫 𝐂𝐡𝐚𝐫𝐚𝐜𝐭𝐞𝐫𝐢𝐳𝐚𝐭𝐢𝐨𝐧 – Assessing critical quality attributes. ✔ 𝐏𝐫𝐨𝐜𝐞𝐬𝐬-𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐈𝐦𝐩𝐮𝐫𝐢𝐭𝐢𝐞𝐬 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 – Ensuring safety and efficacy. Stay tuned to learn more! #GeneTherapy #ViralVectors #AdvancedTherapies

🆕📝 Today we are launching a new page on our website dedicated to our #AdvancedTherapies service! Kymos Group has a specialized team focused on the research and study of the development of test methods for Advanced Therapies (#ATMP), with an Innovation department fully dedicated to the characterization and definition of the quality attributes of gene therapy medicinal products, specifically #ViralVectors such as Adeno-associated virus (AAV), Adenovirus (ADV), and Lentivirus (LT). Our new page contains all the information and specifics about our cutting-edge technologies and techniques for ATMPs. ▶ Visit it to learn more: https://bit.ly/4aS0NMn or contact us via email at commercial@kymos.com if you need more assistance.

Today, on #WorldCancerDay, we stand together with patients, families, and researchers in the fight against cancer. At Kymos Group, we are committed to supporting therapies that improve patients' lives and drive progress in life-saving treatments. Innovation, science, and collaboration—these are the keys to making a difference. #WorldCancerDay #Oncology #CancerResearch #PharmaInnovation

▶ 𝐖𝐡𝐲 𝐭𝐫𝐮𝐬𝐭 𝐊𝐲𝐦𝐨𝐬 𝐆𝐫𝐨𝐮𝐩 𝐟𝐨𝐫 𝐲𝐨𝐮𝐫 𝐈𝐦𝐦𝐮𝐧𝐨𝐠𝐞𝐧𝐢𝐜𝐢𝐭𝐲 𝐀𝐬𝐬𝐞𝐬𝐬𝐦𝐞𝐧𝐭? Novel biological drugs have the potential to trigger immune responses that can affect pharmacokinetics, efficacy, safety, and cross-react with endogenous molecules. At Kymos Group, we provide comprehensive #immunogenicity testing to help you evaluate and mitigate these risks, ensuring the reliability and success of your biologic development. 🔬 𝐃𝐞𝐭𝐞𝐫𝐦𝐢𝐧𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐁𝐢𝐧𝐝𝐢𝐧𝐠 𝐀𝐧𝐭𝐢-𝐃𝐫𝐮𝐠 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐢𝐞𝐬 (#ADA) We apply bioanalytical techniques such as #ELISA and #ECLA to determine ADAs against peptides, proteins, or antibodies. Our assays cover screening, confirmatory, titration, and isotyping. 💡 𝐃𝐞𝐭𝐞𝐫𝐦𝐢𝐧𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐍𝐞𝐮𝐭𝐫𝐚𝐥𝐢𝐳𝐢𝐧𝐠 𝐀𝐧𝐭𝐢-𝐃𝐫𝐮𝐠 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐢𝐞𝐬 (#NAb) NAb determination to assess ADA drug function inhibition using several alternative approaches: ✔ Cell-based assays (#CBA) ✔ Binding assays utilizing ELISA and ECLA 🔗 Learn more about our immunogenicity services at https://bit.ly/4hkCNEh or commercial@kymos.com